STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi.
STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation[1] of potential future sales for Leqembi.
Eisai has retreated from the optimistic view of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains sluggish. In its six-month financial report for the ...
Eisai and Biogen have completed their rolling biologics license application in the US for a subcutaneous formulation of Alzheimer's disease therapy Leqembi previously delayed by the FDA on ...
Seed Therapeutics, a BeyondSpring (Nasdaq: BYSI) spin-off, has inked a collaboration with Japan’s Eisai (TYO: 4523) to discover, develop and commercialize novel molecular glue degraders for multiple ...
1 Day ESAIY -1.53% DJIA -0.31% S&P 500 -1.12% Health Care/Life Sciences 0.63% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback